arrow_back Back to App

This act aims to lower drug prices by prohibiting unfair market practices.

This act aims to prevent pharmaceutical companies from engaging in practices that hinder the introduction of cheaper generic and biosimilar drugs. This means citizens can expect greater availability of more affordable medications, positively impacting their personal finances and access to healthcare. The Federal Trade Commission will have new tools to combat such actions.
Key points
Prohibits drug manufacturers' practices that block competition from cheaper alternatives.
Aims to increase the availability of more affordable generic and biosimilar drugs.
Strengthens the Federal Trade Commission's powers to prosecute unfair practices in the pharmaceutical market.
May lead to lower healthcare costs for citizens.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_2873
Sponsor: Rep. Cicilline, David N. [D-RI-1]
Process start date: 2021-04-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Affordable Prescriptions for Patients Through Promoting Competition Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_2873.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • Prohibits drug manufacturers' practices that block competition from cheaper alternatives.
  • Aims to increase the availability of more affordable generic and biosimilar drugs.
  • Strengthens the Federal Trade Commission's powers to prosecute unfair practices in the pharmaceutical market.
  • May lead to lower healthcare costs for citizens.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Cicilline, David N. [D-RI-1].

What is the latest detailed status?

The latest detailed status is: Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 27 - 16.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health Courts and Law Economy